143 results
Page 2 of 8
8-K
EX-99.1
uqs7qf mspfozndoq5
3 Dec 21
Other Events
7:00am
8-K
EX-99.1
cph8kd92lvvr8
18 Nov 21
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
7:01am
8-K
EX-99.3
zrogwgl7opjeg9pkq
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-99.4
3a1le06qygggiboj2a
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
EX-99.1
8am 2arrb8ag8yl
8 Jun 21
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
7:00am
8-K
EX-99.1
rlx2 j2sk4plc0qviheq
3 May 21
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
7:01am
8-K
EX-99.1
5afri3f
11 Feb 21
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
4:01pm
8-K
EX-99.2
qvplmry3 jy7
11 Feb 21
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
4:01pm
8-K
EX-99.2
h1him
8 Feb 21
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease
2:30pm
8-K
EX-99.2
a34btfgkqg5soru3coop
11 Jan 21
Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook
7:00am
8-K
EX-99.1
0mga8
2 Oct 19
Other Events
7:56am